Triple Antiplatelet Therapy with Cilostazol and Favorable Early Clinical Outcomes after Acute Myocardial Infarction Compared to Dual Antiplatelet Therapy with Standard or Potent P2Y12 Inhibitors

Triple Antiplatelet Therapy with Cilostazol and Favorable Early Clinical Outcomes after Acute Myocardial Infarction Compared to Dual Antiplatelet Therapy with Standard or Potent P2Y12 Inhibitors

Current guidelines for the management of acute myocardial infarction (AMI) recommend potent P2Y12 inhibitors rather than clopidogrel to prevent ischemic events. However, their ischemic benefits are offset by an increased major bleeding risk. We compared the efficacy and safety of triple antiplatelet...

Full description

Bibliographic Details
Main Authors: Sungwook Byun, Su Nam Lee, Sungmin Lim, Eun Ho Choo, Ik Jun Choi, Chan Joon Kim, Donggyu Moon, Mahn-Won Park, Chul Soo Park, Youngkeun Ahn, Myung-Ho Jeong, Kiyuk Chang
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Journal of Clinical Medicine
Subjects:
antiplatelet agent
myocardial infarction
mortality
bleeding
Online Access:https://www.mdpi.com/2077-0383/11/22/6856

Internet

https://www.mdpi.com/2077-0383/11/22/6856

Similar Items